Skip to main content
. 2016 May 26;2016:4386127. doi: 10.1155/2016/4386127

Table 6.

Summary of proof of concept articles on point of care tests for Trichomonas vaginalis from 2010 to 2015.

Study authors and year Summary of results
(summaries are based on descriptions in abstracts and articles)
Performance
Pearce et al. 2013 [51] Electrochemical endpoint assay prototype: a single card performs target DNA extraction, amplification, and electrochemical detection via electrochemical endpoint detection. This prototype is designed to work with the Atlas io platform Sensitivity and specificity of 95.5% (42/44) and 95.7% (44/46), respectively
Limit of detection: 5 TV cells
No cross-reactivity with the nucleic acids from organisms commonly associated with the genitourinary tract

Spizz et al. 2012 [47] Rheonix CARD STI CARD assay: a patented lamination process incorporates all pumps, valves, microchannels, and reaction compartments into an inexpensive disposable plastic device that automatically performs all assay steps. Amplicons detected with Reverse Dot Blot assay Able to detect a minimum of 10 copies of each of the four pathogens (N. gonorrhoeae, C. trachomatis, T. pallidum,and T. vaginalis)